Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I-II Study of HER2 Vaccination With Poly(I) Poly(C12U) (Ampligen) as an Adjuvant in Optimally Treated Breast Cancer Patients

Trial Profile

Phase I-II Study of HER2 Vaccination With Poly(I) Poly(C12U) (Ampligen) as an Adjuvant in Optimally Treated Breast Cancer Patients

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Feb 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rintatolimod (Primary) ; Cancer vaccine HER-2 neu; Granulocyte macrophage colony stimulating factor; Sargramostim
  • Indications Advanced breast cancer; Early breast cancer
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Most Recent Events

    • 04 Feb 2020 Status changed from active, no longer recruiting to completed.
    • 31 Aug 2018 Biomarkers information updated
    • 17 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top